Background The prevalence of inflammatory bowel diseases (IBD) is high in women of
childbearing age. Achieving clinical remission from conception to delivery using current …

Abstract Background and Aims Evidence on the safety of newer biologics during pregnancy
is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during …

Background Women with inflammatory bowel diseases (IBD) often receive biologicals
during pregnancy to maintain disease remission. Data on outcome of vedolizumab‐exposed …

Background Women with inflammatory bowel diseases (IBD) often receive biologics to
maintain remission during pregnancy. Aims To assess maternal and neonatal outcomes in …

Background: Vedolizumab demonstrated different placental pharmacokinetics than other
immunoglobulin G1 antibodies, leading to lower drug levels in cord blood in contrast to …

Background & Aims Biologics are used routinely in pregnant women with inflammatory
bowel disease (IBD), but large-scale data reporting adverse pregnancy outcomes among …

Abstract Background and Aims Vedolizumab is an IgG1 anti-α4β7 integrin antibody
approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety …

OBJECTIVES: Despite encouraging data gathered in inflammatory bowel diseases (IBD)
patients, Vedolizumabs'(VDZ) safety profile in pregnancy is not established. DESIGN: Data …

Background Vedolizumab is a gut‐selective immunoglobulin G1 monoclonal antibody to
α4β7 integrin for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) …

Background Ustekinumab is increasingly used in pregnant women with inflammatory bowel
disease (IBD). Existing safety data are reassuring, but the stability of ustekinumab levels in …